Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

公司代码：688192 公司简称：迪哲医药 迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 | 2026 | 年第一次临时股东会会议须知 1 | | --- | --- | | 2026 | 年第一次临时股东会会议议程 3 | | 一、 | 关于变更注册资本、修订公司章程并办理工商变更登记的议案 6 | | 二、 | 关于改选公司独立董事及调整董事会专门委员会委员的议案 8 | | 三、 | 关于公司发行 H 股股票并在香港联合交易所有限公司上市的议案 11 | | 四、 | 关于公司发行 股股票并在香港联合交易所有限公司上市方案的议案 12 H | | 五、 | 关于本次 H 股股票发行并上市募集资金使用计划的议案 15 | | 六、 | 关于本次 股股票发行并上市决议有效期的议案 16 H | | 七、 | 关于提请股东会授权董事会及其授权人士全权处理与本次 H 股股票发 | | | 行并上市有关事项的议案 17 | | 八、 | 关于就本次 股股票发行并上市修订《公司章程（草案）》及相关议 H | | | 事规则（草案）的议案 24 | | 九、 | 关于确定公 ...

迪哲医药于2021年12月通过第五套标准在科创板上市，获得了关键的发展加速器，极大推动了公司在科 技自立自强道路上的前进步伐。 "作为一家专注创新药物研发与产业化的企业，迪哲医药深知科技创新并非一句口号，它源于对临床未 满足需求的敏锐洞察，更依赖于长期持续的研发投入。"迪哲医药董事长、首席执行官张小林博士表 示，公司始终坚持战略定力，不因短期利润目标而削减研发投入。 "我们注重把研发和商业化打通，让创新真正落地到患者手中。通过两款创新药物成功上市、进入医保 并实现市场放量，我们逐步实现了从研发成果向市场价值的转化。"张小林特别提到，在江苏证监局的 支持下，迪哲医药完成了"科创板八条"以来首家未盈利企业的再融资，为公司下一步发展提供了坚实保 障，"这不仅验证了研发策略的有效性，也让我们意识到，创新型企业通过资本市场的支持，把科技成 果转化为社会价值，为投资者带来长期回报，也进一步夯实了资本市场对创新药企的信心"。 在张小林看来，创新药不仅要服务国内患者，也要具备全球竞争力。通过海外申报和国际临床研究，中 国原创创新药正逐步走向世界，"其中，舒沃哲在中国和美国的获批，充分体现了我们研发成果的国际 竞争力。这既是企 ...

Group 1 - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total [1][3] - Among these, Baili Tianheng led with a fundraising amount of 3.731 billion yuan, followed by Dize Pharmaceutical with 1.773 billion yuan, and Lukang Pharmaceutical with 1.187 billion yuan [3] - The fundraising purposes vary significantly among the companies, with Baili Tianheng and Dize Pharmaceutical focusing on innovative drug research and development [5][6] Group 2 - Baili Tianheng plans to use all raised funds for innovative drug R&D, specifically for platforms related to ADC drugs, multi-specific antibodies, and nuclear medicine [5] - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization, marking it as the first unprofitable company to complete refinancing under the "Science and Technology Innovation Board" framework [5] - Other companies like Aibo Medical and Sanyou Medical have different focuses, with Aibo primarily investing in production line construction and Lukang in high-end formulation manufacturing [5][6] Group 3 - Only two of the eight companies reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and net profit [7] - Baili Tianheng experienced the largest decline in performance, with a revenue drop of 63.52% and a net loss of 4.95 billion yuan, attributed to decreased sales and increased R&D expenses [7][8] - In contrast, Baili Tianheng reported a substantial revenue increase in Q3, driven by successful collaborations and milestone payments [8] Group 4 - Baili Tianheng has also announced plans to issue debt financing tools with a scale of up to 10 billion yuan for various purposes, including R&D and debt repayment [4] - Dize Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] - The competitive landscape in the pharmaceutical industry is intensifying, necessitating continuous investment for companies to maintain technological leadership and market position [8]

Core Viewpoint - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total, indicating a trend towards innovation and strategic investments in the industry [1][3]. Group 1: Fundraising Activities - Eight pharmaceutical stocks have completed private placements this year, raising a total of over 8.5 billion yuan, with Baili Tianheng leading at 3.731 billion yuan [1][3]. - Three companies raised over 1 billion yuan: Baili Tianheng (3.731 billion yuan), Dize Pharmaceutical (1.773 billion yuan), and Lukan Pharmaceutical (1.187 billion yuan) [3]. - The majority of these placements occurred in the first half of the year, with Baili Tianheng's significant placement completed in September [3]. Group 2: Fund Utilization - Baili Tianheng and Dize Pharmaceutical are directing their funds towards innovative drug research and development, with Baili Tianheng focusing entirely on this area [6]. - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization [6]. - Other companies like Aibo Medical and Lukan Pharmaceutical have varied uses for their funds, including production line construction and high-end formulation manufacturing [6][7]. Group 3: Financial Performance - Among the eight companies, only two reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and profit [8]. - Baili Tianheng experienced the largest decline in performance, with a 63.52% drop in revenue and a net loss of 4.95 billion yuan [8]. - However, Baili Tianheng reported a substantial revenue increase in Q3, attributed to successful collaborations and clinical trial milestones [9]. Group 4: Market Insights - The competitive landscape in the pharmaceutical industry is intensifying, necessitating continuous investment in innovation to maintain market position [9]. - Refinancing is viewed as a necessary strategy for pharmaceutical companies facing high R&D costs and long profit cycles, enabling them to accelerate innovation and commercialization [9].

Core Viewpoint - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total, indicating a focus on innovation and strategic investments in the industry [1][3]. Group 1: Fundraising Activities - Eight pharmaceutical stocks have completed private placements this year, raising a total of over 8.5 billion yuan, with Baili Tianheng leading at 3.731 billion yuan [1][3]. - Three companies raised over 1 billion yuan: Baili Tianheng (3.731 billion yuan), Dize Pharmaceutical (1.773 billion yuan), and Lukang Pharmaceutical (1.187 billion yuan) [3]. - The majority of these placements occurred in the first half of the year, with Baili Tianheng's significant placement completed in September [3]. Group 2: Fund Utilization - Baili Tianheng and Dize Pharmaceutical are directing their funds towards innovative drug research and development, with Baili Tianheng focusing entirely on this area [6]. - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization [6]. - Other companies like Aibo Medical and Lukang Pharmaceutical have varied uses for their funds, including production line construction and high-end formulation manufacturing [6][7]. Group 3: Financial Performance - Among the eight companies, only two reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and profit [8]. - Baili Tianheng experienced the largest decline in performance, with a revenue drop of 63.52% and a net loss of 4.95 billion yuan [8]. - However, Baili Tianheng reported a substantial revenue increase in the third quarter, attributed to successful collaborations and clinical trial milestones [9].

瑞财经 吴文婷12月24日，迪哲医药发布公告称，公司于2025年12月24日召开第二届董事会第十八次会议，审议通过了《关于公司发行H股股票并在香港联合 交易所有限公司上市的议案》。 迪哲医药表示，公司将充分考虑现有股东的利益和境内外资本市场的情况，在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其 他期限)选择适当的时机和发行窗口完成本次发行并上市。 公开资料显示，迪哲医药是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。 为深化全球化战略布局，提升公司国际化品牌形象，进一步提升公司核心竞争力，公司拟发行境外上市外资股(以下简称"H股")股票并在香港联合交易所有 限公司(以下简称"香港联交所")主板挂牌上市。 2025年前三季度，公司实现营收为5.86亿元，同比增长73.23%；归母净利润为-5.8亿元，而上年同期为-5.58亿元。 | 项目 | 本报告期 | 本报告期比上 年同期增减变 动幅度(%) | 年初至报告期末 | | --- | --- | --- | --- | | 营业收入 | 231,299,714.08 | 71.46 | 586, ...

Core Viewpoint - The company, Dize Pharmaceutical, announced its plan to issue overseas listed foreign shares (H shares) and list on the main board of the Hong Kong Stock Exchange to enhance its global strategy and brand image [1] Group 1: Strategic Intent - The issuance of H shares aims to deepen the company's globalization strategy and improve its international brand image [1] - The company intends to further enhance its core competitiveness through this issuance [1] Group 2: Shareholder Considerations - The company will take into account the interests of existing shareholders and the conditions of domestic and international capital markets when deciding on the timing and window for the issuance [1] - The decision to proceed with the issuance will be valid for 24 months from the approval of the shareholders' meeting, with the possibility of extension [1]

Core Viewpoint - Dize Pharmaceutical has shown a mixed financial performance with significant revenue growth but a net loss, indicating potential challenges in profitability despite strong sales growth [2] Group 1: Stock Performance - On December 24, Dize Pharmaceutical's stock increased by 0.10% with a trading volume of 64.13 million yuan [1] - The financing buy-in amount on the same day was 4.90 million yuan, while the financing repayment was 2.80 million yuan, resulting in a net financing buy of 2.11 million yuan [1] - As of December 24, the total margin trading balance for Dize Pharmaceutical was 184 million yuan, with a financing balance of 183 million yuan, accounting for 0.67% of the circulating market value [1] Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical achieved a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2] - The net profit attributable to the parent company was -580 million yuan, reflecting a year-on-year decrease of 3.85% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dize Pharmaceutical was 8,806, an increase of 5.01% compared to the previous period [2] - The average number of circulating shares per shareholder was 46,528, which is an increase of 108.97% from the previous period [2] - Notable changes in institutional holdings include Yongying Pharmaceutical Innovation Mixed Fund becoming the fourth largest shareholder with 5.91 million shares, an increase of 2.30 million shares [2]

Core Viewpoint - The company, Dize Pharmaceutical (688192.SH), plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand image, as well as to improve its core competitiveness [1] Group 1 - The company held its 18th meeting of the second board on December 24, 2025, where it approved the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1] - The company is actively discussing the issuance and listing with relevant intermediaries, although specific details regarding the H-share issuance have not yet been finalized [1]